Is There a Role for NFAT Inhibitors in the Prevention of Bone Destruction?
- Mark S. McMahonAffiliated withDepartment of Orthopedic Surgery, Beth Israel Deaconess Medical CenterDepartment of Developmental Biology, Harvard SDM Email author
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Pathologic conditions resulting from excessive bone destruction include osteoporosis, rheumatoid arthritis, metastases, periprosthetic osteolysis, cherubism, and others. A scarcity of molecular targets in bone has thwarted the development of drugs to combat these conditions. Nuclear factor of activated T-cells (NFAT) is a master regulator of osteoclastogenesis and is induced by RANKL. The immunosuppressive drugs, Cyclosporin A and Tacrolimus, inhibit osteoclast formation by targeting the NFAT/calcineurin pathway. These NFAT inhibitors should be considered in the treatment of osteoclastic hyper-resorptive syndromes.
Keywordsosteoclast NFAT Cyclosporin A Tacrolimus calcineurin
- Is There a Role for NFAT Inhibitors in the Prevention of Bone Destruction?
Volume 5, Issue 2 , pp 159-160
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Cyclosporin A
- Industry Sectors
- Mark S. McMahon MD (1) (2)
- Author Affiliations
- 1. Department of Orthopedic Surgery, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA, 02215, USA
- 2. Department of Developmental Biology, Harvard SDM, Research and Education Building 413, 188 Longwood Avenue, Boston, MA, 02115, USA